SSTR4 Inhibitors
1 drugsAbout SSTR4
Somatostatin receptor 4 (SSTR4) is a G protein-coupled receptor that binds somatostatin, inhibiting hormone and neurotransmitter release. It mediates diverse cellular processes and regulates cell growth and hormone secretion.
SSTR4 is a target of interest for drug development due to its role in regulating cell growth and hormone secretion. Currently, there is no genetic evidence directly linking SSTR4 to specific diseases.
One FDA-approved drug, SIGNIFOR (pasireotide), targets SSTR4 and other somatostatin receptors. SIGNIFOR, a small molecule, was first approved in 2012 and is marketed by RECORDATI RARE.
Top SSTR4 Drugs
RECORDATI RARE is the only company with an approved drug targeting SSTR4.
Low market competition suggests potential for new entrants, but also highlights the challenges in developing SSTR4-targeting drugs.
SSTR4 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets SSTR4, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel biologics targeting SSTR4.
SSTR4 Clinical Trials 53 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on SSTR4. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 10 | 9 | 1 | 0 | 90% |
| Phase 2 | 29 | 15 | 11 | 3 | 58% |
| Phase 3 | 8 | 8 | 0 | 0 | 100% |
| Phase 4 | 6 | 4 | 1 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
SSTR4 Drug Approval Timeline (2012 - 2012)
SIGNIFOR was first approved in 2012 and remains the only approved drug targeting SSTR4.
The lack of recent approvals indicates a potentially saturated market or challenges in developing improved SSTR4-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 32 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on SSTR4. A trial counts if an approved drug acting on SSTR4 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.